Century Therapeutics (United States)

company in Philadelphia, United States

IPSC Nasdaq SEC CIK 1850119
Follow Century Therapeutics (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$23.5M +31.9% vs same quarter last year
EPS, diluted −$0.11 +72.5% vs same quarter last year
Operating cash flow −$22.2M +13.1% vs same quarter last year
Operating income −$25.2M +30.2% vs same quarter last year
Revenue by quarter
$4.2M
$109.2M
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$109.2M−$9.6M
FY24$6.6M−$126.6M
FY23$2.2M−$136.7M
FY22$5.2M−$130.9M
FY21-−$95.8M
FY20-−$53.6M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−8000%−6000%−4000%−2000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−15.8%−8.8%
FY24−2096.5%−1920.9%
FY23−6556.9%−6115.1%
FY22−2574.2%−2518.4%
FY21--
FY20--
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$104.7M
FY24−$110.3M
FY23−$102.1M
FY22−$16.6M
FY21−$134M
FY20−$51.1M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Century Therapeutics (United States)
  • Healthcare median
−8000%−6000%−4000%−2000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearCentury Therapeutics (United States)Healthcare median
FY25−8.8%−30.6%
FY24−1920.9%−47%
FY23−6115.1%−58%
FY22−2518.4%−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%